

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for May 2026

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Pharmascience Inc.	PMS-Bilastine	Blexten	BILASTINE	20 mg	tablet	02561565
Jamp Pharma Corporation	Jamp Citalopram	Celexa	CITALOPRAM HYDROBROMIDE	10 mg	tablet	02370085
Apotex Inc.	Elfy	Lolo	NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL	1mg/ 10 mcg; and 10 mcg	tablet	02553481
Marcan Pharmaceuticals Inc.	Mar-Ranolazine XR	Corzyna	RANOLAZINE	500 mg	tablet (extended-release)	02562448